{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sundaramoorthy S"],"funding":["Plan Cancer Systems Biology grant from the ITMO Cancer AVIESAN","Swiss National Science Foundation","FORCE Foundation","Swiss National Science Foundation Professorship grant","Fidinam Foundation grant"],"pagination":["e169647"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11383371"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(14)"],"pubmed_abstract":["The development of targeted therapies offers new hope for patients affected by incurable cancer. However, multiple challenges persist, notably in controlling tumor cell plasticity in patients with refractory and metastatic illness. Neuroblastoma (NB) is an aggressive pediatric malignancy originating from defective differentiation of neural crest-derived progenitors with oncogenic activity due to genetic and epigenetic alterations and remains a clinical challenge for high-risk patients. To identify critical genes driving NB aggressiveness, we performed combined chromatin and transcriptome analyses on matched patient-derived xenografts (PDXs), spheroids, and differentiated adherent cultures derived from metastatic MYCN nonamplified tumors. Bone marrow kinase on chromosome X (BMX) was identif"],"journal":["JCI insight"],"pubmed_title":["Preclinical spheroid models identify BMX as a therapeutic target for metastatic MYCN nonamplified neuroblastoma."],"pmcid":["PMC11383371"],"funding_grant_id":["157468","PP00P3_157468","Health","183724","FORCE Foundation","PP00P3_183724","French National Alliance for Life Sciences"],"pubmed_authors":["Stamenkovic I","Bardet AF","Renella R","Sundaramoorthy S","Riggi N","Kuttler F","Boulay G","Turcatti G","Broye L","Sanalkumar R","Muhlethaler-Mottet A","Balmas Bourloud K","Colombo DF","Rivera MN","Cironi L"],"additional_accession":[]},"is_claimable":false,"name":"Preclinical spheroid models identify BMX as a therapeutic target for metastatic MYCN nonamplified neuroblastoma.","description":"The development of targeted therapies offers new hope for patients affected by incurable cancer. However, multiple challenges persist, notably in controlling tumor cell plasticity in patients with refractory and metastatic illness. Neuroblastoma (NB) is an aggressive pediatric malignancy originating from defective differentiation of neural crest-derived progenitors with oncogenic activity due to genetic and epigenetic alterations and remains a clinical challenge for high-risk patients. To identify critical genes driving NB aggressiveness, we performed combined chromatin and transcriptome analyses on matched patient-derived xenografts (PDXs), spheroids, and differentiated adherent cultures derived from metastatic MYCN nonamplified tumors. Bone marrow kinase on chromosome X (BMX) was identif","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-05-04T06:51:53.328Z","creation":"2025-04-04T00:29:32.332Z"},"accession":"S-EPMC11383371","cross_references":{"pubmed":["39133652"],"doi":["10.1172/jci.insight.169647"]}}